Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 84.5%

Neg 0% Neu 0% Pos 84.5%

Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.